NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 130 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.07 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,416 | -61.2% | 12,538 | -6.0% | 0.00% | – |
| Q2 2023 | $34,538 | -76.1% | 13,335 | -62.3% | 0.00% | – |
| Q1 2023 | $144,461 | -46.1% | 35,407 | -33.7% | 0.00% | -100.0% |
| Q4 2022 | $268,204 | -75.8% | 53,427 | -37.1% | 0.00% | -50.0% |
| Q3 2022 | $1,110,000 | +38.1% | 84,886 | +35.4% | 0.00% | 0.0% |
| Q2 2022 | $804,000 | +81.1% | 62,687 | +115.5% | 0.00% | +100.0% |
| Q1 2022 | $444,000 | +98.2% | 29,091 | +107.0% | 0.00% | 0.0% |
| Q3 2020 | $224,000 | -30.2% | 14,057 | -13.5% | 0.00% | 0.0% |
| Q2 2020 | $321,000 | – | 16,254 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenspring Associates, LLC | 1,573,357 | $47,665,000 | 61.89% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $114,111,000 | 60.06% |
| Column Group LLC | 15,396,116 | $466,502,000 | 42.31% |
| Ponoi II Management, LLC | 1,298,908 | $39,357,000 | 28.68% |
| Ponoi Management, LLC | 1,298,908 | $39,357,000 | 22.52% |
| Euclidean Capital LLC | 2,083,602 | $63,133,000 | 13.36% |
| Aquilo Capital Management, LLC | 1,005,534 | $30,463,000 | 6.33% |
| Octagon Capital Advisors LP | 75,227 | $2,279,000 | 0.79% |
| Jasper Ridge Partners, L.P. | 308,750 | $9,354,000 | 0.41% |
| Point72 Asset Management, L.P. | 1,761,157 | $53,354,000 | 0.26% |